What is Seaport Res Ptn’s Forecast for HIMS FY2024 Earnings?

Hims & Hers Health, Inc. (NYSE:HIMS) – Analysts at Seaport Res Ptn raised their FY2024 earnings estimates for shares of Hims & Hers Health in a research report issued to clients and investors on Monday, November 4th. Seaport Res Ptn analyst A. Kessler now forecasts that the company will post earnings of $0.25 per share for the year, up from their previous estimate of $0.23. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s FY2025 earnings at $0.51 EPS.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 11.67%. The firm had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the prior year, the firm earned ($0.04) earnings per share. The company’s quarterly revenue was up 77.1% compared to the same quarter last year.

Other equities research analysts have also recently issued reports about the company. Truist Financial lifted their target price on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target for the company. Finally, Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday. Eight analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS opened at $23.44 on Thursday. The business has a fifty day moving average of $18.22 and a 200-day moving average of $18.26. Hims & Hers Health has a twelve month low of $6.58 and a twelve month high of $25.74. The firm has a market cap of $5.03 billion, a PE ratio of 53.27 and a beta of 1.06.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC boosted its stake in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares during the period. Quest Partners LLC raised its position in shares of Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after buying an additional 3,507 shares in the last quarter. Van ECK Associates Corp bought a new stake in shares of Hims & Hers Health during the 2nd quarter worth approximately $111,000. CWM LLC boosted its position in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares in the last quarter. Finally, Amalgamated Bank increased its stake in Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Activity at Hims & Hers Health

In other news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the transaction, the chief executive officer now owns 33,502 shares in the company, valued at $487,789.12. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Christiane Pendarvis sold 7,000 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total transaction of $106,050.00. Following the transaction, the director now directly owns 23,917 shares in the company, valued at $362,342.55. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28. Following the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at $487,789.12. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 650,659 shares of company stock worth $11,712,198. 17.71% of the stock is owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.